No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Moffitt Cancer Center Advances Patient Standard of Care by Introducing Needleless Blood Draws

Editor: What To Know

  • Moffitt Cancer Center has adopted a new needle-free method of blood collection for patients in treatment who often need to undergo repeated needle sticks in a day, becoming the first cancer center in Florida to offer this pain-free technology as part of its world-class cancer care.
  • “A needle stick may seem inconsequential, but when repeated numerous times a day on a cancer patient with fragile veins who already carries a significant physical and emotional burden, it can be traumatic,” said Jane Fusilero, vice president and chief nursing officer at Moffitt Cancer Center.
  • What used to be a dreaded, painful experience because of needles is now met with relief and smiles — a transformation that is positive and should be the expectation for patients fighting this disease.

March 24, 2021

Moffitt Cancer Center has adopted a new needle-free method of blood collection for patients in treatment who often need to undergo repeated needle sticks in a day, becoming the first cancer center in Florida to offer this pain-free technology as part of its world-class cancer care.

In its continuing efforts of being at the forefront of innovation, last year the cancer center piloted the needle-free PIVO™ procedure from vascular access technology pioneer Velano Vascular. Since then, thousands of needle sticks have been avoided.

“A needle stick may seem inconsequential, but when repeated numerous times a day on a cancer patient with fragile veins who already carries a significant physical and emotional burden, it can be traumatic,” said Jane Fusilero, vice president and chief nursing officer at Moffitt Cancer Center. “This one seemingly small change, to remove the needle from blood collection, is making an enormous difference to our patients and team members alike. What used to be a dreaded, painful experience because of needles is now met with relief and smiles — a transformation that is positive and should be the expectation for patients fighting this disease.”

Moffitt is adopting this novel procedure across its inpatient population in an effort to bring more humanity to a common yet critical medical procedure, and to do so through a safer alternative to drawing blood from central lines and ports.

“This is a dramatic improvement in how a cancer center can approach vein access with our patients,” said Fusilero. “By shifting collection with this novel needle-free procedure to a traditional peripheral IV line, we’ve been able to significantly enhance our already high quality of care — eliminating pain and discomfort, optimizing practice efficiency, and reducing risk — all while enhancing the patient experience.”

This new standard of care enables what is known as one-stick hospitalization, a practice now in place at many leading health systems around the country. Moffitt Cancer Center is adopting the standard in its fight against cancer.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy